Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
P/B ratio for Co-Diagnostics, Inc. (CODX)
P/B ratio as of 2023: 0.45
According to Co-Diagnostics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.45. At the end of 2022 the company had a P/B ratio of 0.69.
P/B ratio history for Co-Diagnostics, Inc. from 2014 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.45 |
| 2022 | 0.69 |
| 2021 | 1.92 |
| 2020 | 3.73 |
| 2019 | 8.63 |
| 2018 | -17.57 |
| 2017 | 7.51 |
| 2016 | -21.46 |
| 2015 | -56.01 |
| 2014 | 329.22 |